Search filters

List of works by Matthias Scheffler

A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients

scientific article

Benchmarking of mutation diagnostics in clinical lung cancer specimens

scientific article (publication date: 5 May 2011)

Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer

scientific article

Clinical and pathological characteristics of KEAP1- and NFE2L2- mutated non-small cell lung carcinoma (NSCLC).

scientific article published on 3 April 2018

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.

scientific article published on June 2011

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles

scientific article published in September 2011

Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients

scientific article

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib

scientific article published in April 2013

Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography

scientific article published on 21 March 2011

Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center

scientific article published on 30 March 2017

Erratum to: Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis

article

Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors

scientific article published on June 2016

Impact of PET/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis

scientific article published on 18 August 2015

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

scientific article published on 01 October 2018

Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients

scientific article published on July 2015

Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib

scientific article published in January 2015

Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET

scientific article published on 05 November 2018

Monitoring reversible and irreversible EGFR inhibition with erlotinib and afatinib in a patient with EGFR-mutated non-small cell lung cancer (NSCLC) using sequential [18F]fluorothymidine (FLT-)PET.

scientific article published on 20 June 2012

Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors.

scientific article published in March 2010

PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations

scientific article published on 16 March 2016

Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib

scientific article published on 14 April 2012

Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.

scientific article

Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.

scientific article published on 7 November 2011

Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment

scientific article published on 21 May 2020

Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.

scientific article

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort

scientific article published on 20 July 2015

Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma

scientific article

Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib

scientific article published in November 2012

Paulina is supported by:

About Paulina

Help